Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Allogenic hematopoietic stem cell transplantation in two siblings with adult metachromatic leukodystrophy and a systematic literature review

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{7c26b6efb0a54a2d8d5112789c915645,
title = "Allogenic hematopoietic stem cell transplantation in two siblings with adult metachromatic leukodystrophy and a systematic literature review",
abstract = "Two siblings were diagnosed with adult metachromatic leukodystrophy (MLD) and treated with hematopoietic stem cell transplantation (HSCT). While the older sibling was symptomatic at the time of diagnosis, her younger brother was diagnosed and transplanted at the presymptomatic state. We describe patients' clinical, biochemical, and genetic features, as well as neuropsychological and neurophysiological test results, and brain magnetic resonance imaging from pretransplantation and posttransplantation assessments. Both patients converted to complete donor chimerism and arylsulfatase A levels normalized 3 months posttransplantation. Twelve months posttransplantation, neurological and neuropsychological assessment for both patients showed stabilization, and they remained stable for the 38 months long observation period. To assess the effect of HSCT used as treatment for the rare, adult MLD subtype on survival and stabilization, we performed a systematic literature review and included 7 studies with a total of 26 cases. Of these 26 cases, 6 patients died of HSCT-related complications and 2 patients had graft rejection. Of the remaining 18 patients, 2 patients improved after HSCT, 13 patients stabilized, and 3 patients progressed, suggesting that HSCT potentially benefits adult MLD patients. Larger studies focusing on this subtype are needed and recommendations on criteria for HSCT in adult MLD need to be evolved.",
author = "Cecilie Videb{\ae}k and Jette Stokholm and Henrik Sengel{\o}v and Fjeldborg, {Lone U} and Larsen, {Vibeke Andr{\'e}e} and Christian Krarup and Nielsen, {J{\o}rgen E} and Sabine Gr{\o}nborg",
note = "{\textcopyright} 2021 The Authors. JIMD Reports published by John Wiley & Sons Ltd on behalf of SSIEM.",
year = "2021",
month = jul,
doi = "10.1002/jmd2.12221",
language = "English",
volume = "60",
pages = "96--104",
journal = "JIMD Reports",
issn = "2192-8304",
publisher = "Springer Berlin",
number = "1",

}

RIS

TY - JOUR

T1 - Allogenic hematopoietic stem cell transplantation in two siblings with adult metachromatic leukodystrophy and a systematic literature review

AU - Videbæk, Cecilie

AU - Stokholm, Jette

AU - Sengeløv, Henrik

AU - Fjeldborg, Lone U

AU - Larsen, Vibeke Andrée

AU - Krarup, Christian

AU - Nielsen, Jørgen E

AU - Grønborg, Sabine

N1 - © 2021 The Authors. JIMD Reports published by John Wiley & Sons Ltd on behalf of SSIEM.

PY - 2021/7

Y1 - 2021/7

N2 - Two siblings were diagnosed with adult metachromatic leukodystrophy (MLD) and treated with hematopoietic stem cell transplantation (HSCT). While the older sibling was symptomatic at the time of diagnosis, her younger brother was diagnosed and transplanted at the presymptomatic state. We describe patients' clinical, biochemical, and genetic features, as well as neuropsychological and neurophysiological test results, and brain magnetic resonance imaging from pretransplantation and posttransplantation assessments. Both patients converted to complete donor chimerism and arylsulfatase A levels normalized 3 months posttransplantation. Twelve months posttransplantation, neurological and neuropsychological assessment for both patients showed stabilization, and they remained stable for the 38 months long observation period. To assess the effect of HSCT used as treatment for the rare, adult MLD subtype on survival and stabilization, we performed a systematic literature review and included 7 studies with a total of 26 cases. Of these 26 cases, 6 patients died of HSCT-related complications and 2 patients had graft rejection. Of the remaining 18 patients, 2 patients improved after HSCT, 13 patients stabilized, and 3 patients progressed, suggesting that HSCT potentially benefits adult MLD patients. Larger studies focusing on this subtype are needed and recommendations on criteria for HSCT in adult MLD need to be evolved.

AB - Two siblings were diagnosed with adult metachromatic leukodystrophy (MLD) and treated with hematopoietic stem cell transplantation (HSCT). While the older sibling was symptomatic at the time of diagnosis, her younger brother was diagnosed and transplanted at the presymptomatic state. We describe patients' clinical, biochemical, and genetic features, as well as neuropsychological and neurophysiological test results, and brain magnetic resonance imaging from pretransplantation and posttransplantation assessments. Both patients converted to complete donor chimerism and arylsulfatase A levels normalized 3 months posttransplantation. Twelve months posttransplantation, neurological and neuropsychological assessment for both patients showed stabilization, and they remained stable for the 38 months long observation period. To assess the effect of HSCT used as treatment for the rare, adult MLD subtype on survival and stabilization, we performed a systematic literature review and included 7 studies with a total of 26 cases. Of these 26 cases, 6 patients died of HSCT-related complications and 2 patients had graft rejection. Of the remaining 18 patients, 2 patients improved after HSCT, 13 patients stabilized, and 3 patients progressed, suggesting that HSCT potentially benefits adult MLD patients. Larger studies focusing on this subtype are needed and recommendations on criteria for HSCT in adult MLD need to be evolved.

UR - http://www.scopus.com/inward/record.url?scp=85121691783&partnerID=8YFLogxK

U2 - 10.1002/jmd2.12221

DO - 10.1002/jmd2.12221

M3 - Journal article

C2 - 34258145

VL - 60

SP - 96

EP - 104

JO - JIMD Reports

JF - JIMD Reports

SN - 2192-8304

IS - 1

ER -

ID: 68397660